These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31882490)

  • 21. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.
    Tokuhara K; Ueyama Y; Nakatani K; Yoshioka K; Kon M
    World J Surg Oncol; 2016 Apr; 14():136. PubMed ID: 27129578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
    Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
    Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
    Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
    Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic analysis of rectal cancer patients after neoadjuvant chemoradiotherapy: different prognostic factors in patients with different TRGs.
    Tang YL; Li DD; Duan JY; Wang X
    Int J Colorectal Dis; 2024 Jun; 39(1):93. PubMed ID: 38896374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor location as an indication for adjuvant radiotherapy in pT3N0 rectal cancer after surgery.
    Peng HH; Zhou XH; Zhou TC; Qiu XS; You KY
    Radiat Oncol; 2019 Jan; 14(1):8. PubMed ID: 30651116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study on the relationship between tumor regression grade and lymph node regression grade].
    Zhao Q; Fu C; Yu E; Zhang W; Meng R; Wang H; Hao L; Wang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1050-1054. PubMed ID: 28900999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery.
    Ide S; Toiyama Y; Okugawa Y; Oki S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Kobayashi M; Ohi M; Araki T; Kusunoki M
    Anticancer Res; 2017 Oct; 37(10):5797-5804. PubMed ID: 28982904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of neoadjuvant rectal score in prognosis and adjuvant chemotherapy decision-making in locally advanced rectal cancer following neoadjuvant short-course radiotherapy and consolidation chemotherapy].
    Zeng Q; Tang Y; Zhou HT; Li N; Liu WY; Chen SL; Li S; Lu NN; Fang H; Wang SL; Liu YP; Song YW; Li YX; Jin J
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):335-343. PubMed ID: 38644269
    [No Abstract]   [Full Text] [Related]  

  • 33. Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer.
    Mukai T; Uehara K; Aiba T; Ogura A; Tsuzuki T; Tanaka A; Sando M; Ohara N; Sato Y; Hattori N; Nakayama G; Kodera Y; Nagino M
    Surg Today; 2020 Aug; 50(8):912-919. PubMed ID: 31989238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer.
    McMahon RK; O'Cathail SM; Nair H; Steele CW; Platt JJ; Digby M; McDonald AC; Horgan PG; Roxburgh CSD
    Colorectal Dis; 2023 Sep; 25(9):1783-1794. PubMed ID: 37485654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
    Sakr A; Elsherbiny M; Abdel Moneim R; Shaaban S; Aldaly M
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1717-1723. PubMed ID: 32592369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different Impacts of Preoperative Radiotherapy and Chemoradiotherapy on Oncological Outcomes in Patients with Stages II and III Lower Rectal Cancer: A Propensity Score Analysis.
    Takiyama H; Kawai K; Ishihara S; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Nozawa H; Morikawa T; Watanabe T
    Dig Surg; 2018; 35(3):212-219. PubMed ID: 28637039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
    Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
    J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Postoperative Chemoradiotherapy versus Chemotherapy Alone on Recurrence and Survival in Patients with Stage II and III Upper Rectal Cancer: A Propensity Score-Matched Analysis.
    Song C; Song S; Kim JS; Oh HK; Kim DW; Lee KW; Kim JH; Eom KY; Kim IA; Kang SB
    PLoS One; 2015; 10(4):e0123657. PubMed ID: 25902069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
    Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
    Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.